NEW YORK (GenomeWeb News) — Cellzome has extended until June 2008 its research agreement with Novartis, the company said yesterday.
Under the terms of the partnership, Cellzome will continue to use its proteomics and pathway mapping experience to identify therapeutic and pharmacological targets to Novartis compounds.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.